Core Insights - Edwards Lifesciences Corporation (EW) is valued at a market cap of $45.2 billion and specializes in products for advanced cardiovascular diseases, particularly known for its SAPIEN transcatheter aortic valve replacement products [1] - The company is set to announce its fiscal Q3 earnings for 2025 on October 30, 2023, with analysts expecting a profit of $0.59 per share, a decrease of 11.9% from the previous year [2] Financial Performance - For fiscal 2025, analysts project EW to report a profit of $2.50 per share, reflecting a 2.9% increase from $2.43 per share in fiscal 2024, with further growth expected to $2.78 per share in fiscal 2026, an 11.2% year-over-year increase [3] - In Q2, EW reported an 11.9% year-over-year revenue increase to $1.5 billion, surpassing consensus estimates by 2.7%, and an adjusted EPS of $0.67, which was 8.1% higher than the previous year [5] Stock Performance - EW's shares have increased by 17.9% over the past 52 weeks, outperforming the S&P 500 Index's 17.8% rise and the Health Care Select Sector SPDR Fund's 4.4% decline during the same period [4] - Following the release of better-than-expected Q2 results, EW's shares surged by 5.5% in the subsequent trading session [5] Analyst Ratings - Wall Street analysts maintain a "Moderate Buy" rating for EW, with 15 out of 31 analysts recommending "Strong Buy," one suggesting "Moderate Buy," 14 advising "Hold," and one indicating "Strong Sell" [6] - The mean price target for EW is set at $86.83, suggesting a potential upside of 12.7% from current levels [6]